1. Clinical Overview
A potent topical combination therapy consisting of a super-high potency corticosteroid (Clobetasol Propionate) and a bacteriostatic antibiotic (Fusidic Acid). It is primarily indicated for the treatment of inflammatory dermatoses complicated by or at high risk of secondary bacterial infections, particularly those caused by Staphylococcus aureus, including methicillin-resistant strains (MRSA). Clobetasol provides rapid and potent anti-inflammatory, anti-pruritic, and vasoconstrictive effects, while Fusidic Acid targets gram-positive bacterial pathogens. This combination is highly effective but carries significant risks of local and systemic side effects due to the potency of clobetasol, necessitating short-term, supervised use.
| Onset | Duration | Bioavailability |
|---|---|---|
| Anti-pruritic and anti-inflammatory effects can be observed within 3-6 hours. Significant clinical improvement typically seen within 24-48 hours. | Vasoconstrictive effect can last up to 72 hours. Clinical effects persist for the duration of application, but systemic absorption can have longer-lasting suppressive effects on the HPA axis. | Topical bioavailability is variable (1-5%) depending on skin integrity, site of application, occlusion, and vehicle. Systemic absorption increases with application to large areas, thin skin (face, groin), broken skin, or under occlusion. |
2. Mechanism of Action
The combination exerts a dual mechanism: 1) Clobetasol propionate binds to intracellular glucocorticoid receptors, modulating gene transcription. This leads to the synthesis of anti-inflammatory proteins (lipocortin) and inhibition of pro-inflammatory mediators (cytokines, leukotrienes, prostaglandins). It also causes vasoconstriction. 2) Fusidic acid inhibits bacterial protein synthesis by binding to elongation factor G (EF-G), preventing translocation on the ribosome and thus inhibiting bacterial growth, specifically against gram-positive organisms.
3. Indications & Uses
- Severe corticosteroid-responsive dermatoses with confirmed or suspected secondary bacterial infection (e.g., infected eczema, infected psoriasis)
- Bullous dermatoses with superinfection
- Lichen simplex chronicus with infection
- Severe contact dermatitis with bacterial complication
4. Dosage & Administration
Adult Dosage: Apply a thin film to the affected area once or twice daily. Treatment should be limited to 2 consecutive weeks. The maximum weekly dose should not exceed 50 grams of cream/ointment.
Administration: 1. Wash and dry hands and affected area. 2. Apply a thin layer and rub gently until it disappears. 3. Do not bandage, wrap, or cover the treated area unless specifically directed by a physician (occlusive dressing dramatically increases absorption and risk of side effects). 4. Avoid contact with eyes, mouth, nose, and mucous membranes. 5. Wash hands after application unless hands are the treatment area.
5. Side Effects
Common side effects may include:
- Local burning or stinging sensation (especially on broken skin)
- Itching (pruritus)
- Dryness of skin
- Erythema
- Skin irritation
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Other Topical Corticosteroids | Additive risk of local and systemic side effects, including HPA axis suppression. | Major |
| Oral Corticosteroids (e.g., Prednisolone) | Increased risk of systemic corticosteroid effects and HPA axis suppression. | Major |
| Topical Retinoids (e.g., Tretinoin) | Increased risk of severe local irritation and skin atrophy. | Moderate |
| Topical Immunosuppressants (e.g., Tacrolimus, Pimecrolimus) | Theoretical increased risk of infection and malignancy; concurrent use not recommended. | Moderate |
| CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin) | May inhibit metabolism of systemically absorbed clobetasol, increasing systemic exposure and toxicity risk. | Moderate |
7. Patient Counselling
- DO use exactly as prescribed by your doctor. Do not use longer or more frequently than directed.
- DO apply a thin layer only to the affected area.
- DO wash your hands before and after application (unless hands are being treated).
- DO report any lack of improvement after 1 week or worsening of condition.
- DON'T use on the face, groin, or underarms unless specifically instructed.
- DON'T bandage, wrap, or cover the area with tight clothing unless told to do so.
- DON'T use for any condition other than the one for which it was prescribed.
- DON'T share this medicine with others.
8. Toxicology & Storage
Overdose: Topical overdose manifests as exaggerated local side effects: severe skin atrophy, striae, telangiectasia, ulceration, and signs of systemic absorption (Cushingoid features, hyperglycemia, adrenal suppression, hypertension). Acute ingestion of the topical product is unlikely but could cause GI upset.
Storage: Store at room temperature (15-25°C), protected from light and moisture. Do not freeze. Keep the tube tightly closed. Keep out of reach and sight of children. Do not use after the expiry date printed on the pack.